- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04231682
A Study to Evaluate Efficacy and Safety of Denosumab for Prevention and Treatment of Osteoporosis in 1st Time Liver Transplant Recipients.
June 24, 2020 updated by: Catherine Anastasopoulou, MD, PhD, FACE, Albert Einstein Healthcare Network
A Prospective Randomized Double-Blind, Placebo-Controlled Phase 2 Study Evaluating the Efficacy and Safety of Early Administration of Denosumab 60mg for Prevention and Treatment of Osteoporosis in First-time Liver Transplant Recipients
Organ transplant recipients are known to suffer from bone loss and subsequent fractures after the transplant operation with the most rapid bone loss occurring within the first 3-12 months.
Guidelines for prevention and treatment of this serious complication are only written by individual medical societies interested in each organ (separate kidney from liver or heart transplants management) and they are based on studies done with limited medications choices.
The majority of studies are done with the use of bisphosphonates, and there are very limited, or no data, on the effect of other medications used for Osteoporosis, including the use of denosumab.
This study will focus on the evaluation of the efficacy and safety of denosumab 60mg use early (within first 3 months) after Liver Transplantation in the management of bone loss and prevention of fragility fractures.
Different tests will be used to study the effect of the medication on the skeleton, including imaging studies as well as specific labwork.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age >=18 years old
- First-time Liver transplant Recipients
- All men, postmenopausal women and women with history of hysterectomy or tubal ligation
- Patients who have not been treated with medications for Osteoporosis within the past 12 months before the liver transplant
- Patients able and agreeable to follow up at out Institution for the duration of the study
- Patients hospitalized for less than 45 consecutive days after the liver transplant surgery
- Patients with GFR>30ml/min (calculated by Cockcroft-Gault equation, see Table 3 for details)
- Patients with corrected Calcium >= 8.5
- Patients with PTH intact levels WNL (as per lab values)
- Patients with vit D>=20; NOTE: patients with vit D <20 will be treated with high dose Ergocalciferol 50,000 units daily and rechecked in 2 weeks
- Patients with t-score >=-3.5 at all sites checked by DEXA scan
- Patients agree to sign an informed consent form to be in the study
- Can be treated with denosumab or placebo within 3 months from the liver transplant date
Exclusion Criteria:
- Patients with previous transplants
- Patients that are getting 2 simultaneous transplants, like combined kidney and liver transplants
- Age < 18 year old
- Patients hospitalized for over 45 days after the liver transplant surgery
- Patients with GFR< 30ml/min
- Patients with hypocalcemia defined as corrected calcium < 8.5
- Patients with extensive dental problems, previous hx of Osteonecrosis of the jaw (ONJ) and/or high risk for developing ONJ
- Patients with current Hyperthyroidism
- Patients with current Primary Hyperparathyroidism defined by the combination of elevated calcium and PTH intact levels
- Patients with severe Osteoporosis as defined by t-score <-3.5 at any site shown by DEXA scan
- Women of reproductive age without history of tubal ligation or hysterectomy
- Patients who cannot read or understand the Informed Consent Document or study instructions
- Patients with diagnosis of dementia, or otherwise unable to give informed consent
- Patients unable to follow up in our Institution for the duration of the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Denosumab receiving group.
Patients in this arm will receive denosumab injection 60 mg subcutaneously every 6 months.
(A total of 4 injections)
|
Use of denosumab in post liver transplant patient for prevention and management of osteoporosis and bone loss.
|
Placebo Comparator: Placebo receiving group.
Patients in this arm will receive Placebo injection subcutaneously every 6 months.
(A total of 4 injections)
|
Use of placebo in post liver transplant patient for prevention and management of osteoporosis and bone loss.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The percentage changes in bone mass calculated by DEXA scan t-score of Lumbar Spine in the intervention and control groups at 12 months.
Time Frame: 12 months
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The percentage changes in bone mass calculated by DEXA scan t-score of Femoral Neck, Total Hip and Wrist in the intervention and control groups at 12 months.
Time Frame: 12 months
|
12 months
|
The percentage changes in bone mass calculated by DEXA scan t-score of Lumbar Spine, Femoral Neck, Total Hip and Wrist in the intervention and control groups at 24 months.
Time Frame: 24 months
|
24 months
|
The vertebral and non-vertebral fracture incidence at 12 and 24 months.
Time Frame: 12 and 24 months
|
12 and 24 months
|
The percentage changes of biochemical markers of variables of bone turnover (BSAP, CTX and PINP) from baseline to 6, 12, 18 and 24 months after 1st medication administration.
Time Frame: 6, 12, 18 and 24 months
|
6, 12, 18 and 24 months
|
The percentage changes of creatinine, Calcium, Magnesium, Phosphorus, PTH intact and 25-Vit D levels from baseline to 6, 12, 18 and 24 months after the 1st medication administration.
Time Frame: 6, 12, 18 and 24 months
|
6, 12, 18 and 24 months
|
The percentage of patients developing infections, rejection episodes, hospitalizations or ED visits during the study period.
Time Frame: 24 months
|
24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Catherine Anastasopoulou, MD, PhD, Einstein Medical Center Philadelphia.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
July 1, 2020
Primary Completion (Anticipated)
January 1, 2024
Study Completion (Anticipated)
January 1, 2025
Study Registration Dates
First Submitted
January 3, 2020
First Submitted That Met QC Criteria
January 14, 2020
First Posted (Actual)
January 18, 2020
Study Record Updates
Last Update Posted (Actual)
June 26, 2020
Last Update Submitted That Met QC Criteria
June 24, 2020
Last Verified
June 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB-2020-300
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoporosis
-
Radius Health, Inc.CompletedOsteoporosis | Osteoporosis Risk | Osteoporosis, Postmenopausal | Osteoporosis Fracture | Osteoporosis, Age-Related | Osteoporosis Localized to Spine | Osteoporosis Senile | Osteoporosis of Vertebrae | Osteoporosis VertebralUnited States
-
Radius Health, Inc.CompletedOsteoporosis | Age Related Osteoporosis | Osteoporosis, Age-Related | Osteoporosis Localized to Spine | Osteoporosis Senile | Osteoporosis of VertebraeUnited States, Poland, Italy
-
Hoffmann-La RocheCompletedPostmenopausal OsteoporosisUnited States
-
Hoffmann-La RocheCompletedPost Menopausal OsteoporosisUnited States, Puerto Rico
-
Centre Hospitalier Universitaire de Saint EtienneMinistry of Health, FranceRecruitingPost Menopausal OsteoporosisFrance
-
AmgenCompletedPost Menopausal OsteoporosisFrance
-
Hoffmann-La RocheCompletedPost Menopausal OsteoporosisUnited States
-
Hoffmann-La RocheCompletedPost Menopausal OsteoporosisSpain, South Africa, Germany, Mexico, United States, Canada, France, United Kingdom, Italy, Belgium, Australia, Poland, Denmark, Hungary, Czech Republic, Norway
-
Hoffmann-La RocheGlaxoSmithKlineCompletedPost Menopausal OsteoporosisFrance
-
Novartis PharmaceuticalsCompletedPost-menopausal OsteoporosisColombia, Belgium, Sweden, Hong Kong, United States, Hungary, Switzerland, Australia, Germany, Italy, Canada, Poland, Argentina, Thailand, Norway, New Zealand, France, Finland
Clinical Trials on Denosumab Injection
-
Shanghai Biomabs Pharmaceutical Co., Ltd.RecruitingPostmenopausal OsteoporosisChina
-
Wuhan Union Hospital, ChinaNot yet recruitingSarcopenia | Osteoporosis | DenosumabChina
-
Qilu Pharmaceutical Co., Ltd.Unknown
-
Mabwell (Shanghai) Bioscience Co., Ltd.Completed
-
Qilu Pharmaceutical Co., Ltd.Unknown
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.Recruiting
-
Qilu Pharmaceutical Co., Ltd.Completed
-
Kyoto Prefectural University of MedicineActive, not recruiting
-
Shanghai Biomabs Pharmaceutical Co., Ltd.CompletedPostmenopausal OsteoporosisChina